Delcath Systems Inc (DCTH)
Healthcare
Medical Devices
12.20 $
+1.5%
vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Delcath Systems Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
0.4$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
35Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
82.8%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.5
Performance
Perf. 1M
Price performance over the last month.
18.30%
Perf. 3M
Price performance over the last 3 months.
44.40%
Perf. 6M
Price performance over the last 6 months.
25.50%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
21.70%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-13.1%
Perf. 1Y
Price performance over the last 12 months.
-7.69%
Perf. 3Y
Price performance over the last 3 years.
21.40%
Perf. 5Y
Price performance over the last 5 years.
10.87%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
25.8
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
1.6
P/B
Price-to-book ratio: market value relative to book equity.
–
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
4.6
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
294.2
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
21.7
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
86.0%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
0.6%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
0.6%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-1.0%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
–
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
5.00
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
4 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
26.30%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
-66.70%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
129.08%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
26.52%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
15.70%
Dividend
This stock currently pays no dividend.
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
60
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
10
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
4 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
B (56 out of 100)
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
5.00
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
Current Price
12.20 $
Price Target (average)
21.35 $
The price target sits 75.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
6. Aug 2026
· before the open
· Q2 2026
- Expected Earnings per Share
- -0.16 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.10 | – | 15 | 2,701.50 | -22.50 | -1 | -1 |
| 2025: Q1 | 0.03 | – | 20 | 530.30 | 5.40 | 2 | 2 |
| 2025: Q2 | 0.08 | – | 24 | 211.00 | 11.20 | 7 | 7 |
| 2025: Q3 | 0.02 | -55.50 | 21 | 83.60 | 4.00 | 5 | 4 |
| 2025: Q4 | -0.05 | – | 21 | 37.30 | -9.10 | 8 | 8 |
| 2026: Q1 | -0.03 | -200.10 | 25 | 26.30 | -4.30 | 1 | 0 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Delcath Systems, Inc., ein interventionell-onkologisches Unternehmen, konzentriert sich auf die Behandlung von primären und metastasierten Leberkrebserkrankungen in den USA und Europa.
| Employees | 156 |
|---|---|
| Headquarters | Queensbury, NY |
| Website | delcath.com |
| IPO Date | 29. May 2018 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gerard J. Michel MBA, MS | CEO & Director | 1963 |
| Martha S. Rook Ph.D. | Chief Operating Officer | 1971 |
| Vojislav Vukovic M.D., M.Sc., Ph.D. | Chief Medical Officer | 1967 |
| Sandra Pennell CPA | Chief Financial Officer | 1979 |
| David Hoffman J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 1970 |
| Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 1965 |
| Kevin Muir | Chief Commercial Officer | – |
| Michael Brunner M.D. | Senior Vice President of Interventional Oncology | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.